Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation-Reference-Cited by-同舟云学术

Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation

Published:2021-03-31 Issue:4 Volume:19 Page:1112-1115
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J. Thromb. Haemost.

Author:

Khorsand Nakisa¹,Beyer‐Westendorf Jan²,Sarode Ravi³,Schulman Sam⁴⁵,Meijer Karina⁶

Affiliation:

1. Department Pharmacy OLVG Amsterdam the Netherlands

2. Thrombosis Research Unit Center of Vascular Diseases Dresden University Hospital ‘Carl Gustav Carus’ Dresden Germany

3. Division of Transfusion Medicine and Hemostasis Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA

4. Department of Medicine McMaster University Hamilton Ontario Canada

5. Department of Obstetrics and Gynecology I.M. Sechenov First Moscow State Medical University Moscow Russia

6. Department of Hematology University of Groningen University Medical Center Groningen Groningen the Netherlands

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15222

Reference9 articles.

1. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH

2. Treatment of apixaban‐ and rivaroxaban‐associated major bleeding using 4‐factor prothrombin complex concentrate;Sheikh‐Taha M;Intern Emerg Med,2018

3. Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis

4. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding

5. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization and safety of off-label prothrombin complex concentrate (four-factor prothrombin complex concentrate) in a surgical population;Blood Coagulation & Fibrinolysis;2024-02-28

2. Utilization and safety of off-label prothrombin complex concentrate (4F-PCC) in a nonsurgical population;Blood Coagulation & Fibrinolysis;2024-02-28

3. Thrombin generation, bleeding and hemostasis in humans: Protocol for a scoping review of the literature;PLOS ONE;2023-11-01

4. Comparison of outcomes for fixed and weight-based four-factor prothrombin complex concentrate dosing regimens;European Journal of Hospital Pharmacy;2023-09-19

5. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes;Thrombosis Research;2023-08